Table 2 Treatments And Outcomes For The Three Responder Groups

Drug Treatments

One DMARD

137/163 (84%)

34/40 (85%)

64/76 (84%)

39/47 (83%)

NS

Two DMARDs

63/163 (39%)

10/40 (25%)

35/76 (46%)

18/47 (38%)

NS

Three DMARDs

4/163 (3%)

0

3/76 (4%)

1/47 (2%)

NS

Steroid Injections

70/163 (43%)

13/40 (33%)

31/76 (41%)

26/47 (55%)

NS

One Biologic

49/163 (30%)

2/40 (5%)

23/76 (30%)

24/47 (51%)

< 0.001

Two Biologics

7/163 (4%)

1/40 (3%)

2/76 (3%)

4/47 (9%)

NS

Three Biologics

2/163 (1%)

0

1/76 (1%)

1/47 (2%)

NS

Management Approaches

Attended 8 or more monitoring visits

139/161 (86%)

34/40 (85%)

65/74 (88%)

40/47 (85%)

NS

Followed management algorithm at each visit

1122/1469 (76%)

330/373 (88%)

519/681 (76%)

273/415 (66%)

< 0.001

Pain management at each visit

1055/1533 (69%)

240/387 (62%)

501/708 (71%)

314/438 (72%)

0.004

Fatigue management at each visit

825/1533 (54%)

200/387 (52%)

384/710 (54%)

241/436 (55%)

NS

End-Point Outcomes

DAS28-ESR Change, Mean (SD)

1.0 (1.4)

2.1 (0.8)

0.8 (1.3)

0.3 (1.2)

< 0.001

DAS28-ESR Remission, Number (%)

48/147 (29%)

28/36 (70%)

18/67 (24%)

2/44 (4%)

< 0.001

HAQ Change, Mean (SD)

0.2 (0.5)

0.4 (0.5)

0.2 (0.6)

0.1 (0.4)

NS

HAQ < 1.0

60/140 (42%)

25/33 (66%)

31/65 (41%)

12/42 (26%)

< 0.001

Pain Change, Mean (SD)

13 (32)

27 (27)

12 (31)

2 (32)

0.002

Pain < 20

80/148 (49%)

32/36 (80%)

37/68 (54%)

11/44 (24%)

< 0.001

Fatigue Change, Mean (SD)

18 (32)

27 (30)

21 (32)

6 (30)

0.008

Fatigue < 20

51/148 (31%)

23/36 (68%)

22/68 (29%)

6/44 (13%)

< 0.001